Eisai: Halaven(R) Receives Approval In Japan For The Treatment Of Inoperable And Recu
Eisai Co., Ltd. (TSE: 4523) announced today that it has received approval to market its novel anticancer Halaven(R) Injection 1mg (eribulin mesylate) in Japan for the treatment of inoperable and recurrent breast cancer...